-
MTM could take chunk out of the $290 billion in annual healthcare costs
WASHINGTON — Sen. Kay Hagan, D-N.C., argued before the Senate Thursday around the value that increased access to medication therapy management can deliver to overall health care — that includes cutting into the $290 billion in annual costs associated with medication nonadherence and preventing as many as 89,000 premature deaths.
-
Sun's generic Razadyne ER granted regulatory approval
MUMBAI, India — The Food and Drug Administration has approved a generic Alzheimer’s disease treatment from Sun Pharmaceutical Industries.
Sun said Thursday that the FDA had approved its galantamine hydrobromide extended-release capsules in the 8-mg, 16-mg and 24-mg strengths.
The drug is a generic version of Johnson & Johnson’s Razadyne ER, which has annual sales of about $50 million, according to Sun.